The Specimen Core will provide SPORE investigators with well-characterized biologic specimens, including tissues, blood, and tissue derivatives, that are essential for achieving the aims ofthe projects. The Specimen Core has a large repository of paraffin blocks, frozen samples, plasma, serum, and bone marrow that spans the entire spectrum of prostate cancer. The repository includes primary tumors and metastases from therapy-resistant tumors and tumors derived from radical prostatectomy specimens from patients given novel preoperative therapies as part of studies conducted at The University of Texas M. D. Anderson Cancer Center and other, multi-institutional efforts. This material, supplemented in select cases with matching biopsy specimens, plasma, serum, and bone marrow aspirates collected before therapy, will provide SPORE investigators with optimal tissue samples with which to address the proposed basic and translational research tissue requirements of the projects. We have also established biologic models (cell lines and xenografts) relevant to the projects. Tissue requests and approval by the Tissue Acquisition and Distribution Committee will be handled electronically. Tissue derivatives, including tissue microarrays, cRNA, and DNA, will optimize the use of limited samples and enhance collaboration among investigators at M. D. Anderson and other institutions. Structured information derived from standardized, high-throughput assays of differential gene expression, both of protein (immunohistochemistry) and RNA (oligonucleotide arrays and multiplexed PCR), will be available to individual SPORE investigators to facilitate modular and gene network analysis in specific clinical contexts. A unique feature of the Specimen Core will be the ability to link comprehensive clinical and pathologic information to the morphologic and molecular characterization of selected pathways. This linkage will be accomplished, in cooperation with the Biostatistics and Bioinformatics Core, by using a Web-based portal. By using this Web-based system to access and query SPORE data, we will pool laboratory resources, facilitate the translational research proposed in the projects, and accelerate successful achievement of the proposed aims.

Public Health Relevance

^ The Specimen Core will collect, store and distribute tissue and blood samples from patients with prostate cancer. The Core will also create and maintain cell lines and xenografts from samples of prostate cancer tissues. These materials are essential to conduct the projects of this SPORE proposal. The Core will provide technical support and pathologic expertise to the investigators and will link the clinical and pathologic information to the results obtained from the various experiments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA140388-02
Application #
8135434
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
2
Fiscal Year
2010
Total Cost
$248,180
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Zhang, Wei; Liu, Bo; Wu, Wenhui et al. (2018) Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res 24:696-707
Monroig-Bosque, Paloma Del C; Shah, Maitri Y; Fu, Xiao et al. (2018) OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. Sci Rep 8:13106
Basourakos, Spyridon P; Davis, John W; Chapin, Brian F et al. (2018) Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int 121:69-76
Pan, Tianhong; Lin, Song-Chang; Yu, Kai-Jie et al. (2018) BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia 20:32-43
Yu-Lee, Li-Yuan; Yu, Guoyu; Lee, Yu-Chen et al. (2018) Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGF?RIII-p38MAPK-pS249/T252RB Pathway. Cancer Res 78:2911-2924
Luo, Yong; Azad, Abul Kalam; Karanika, Styliani et al. (2018) Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. Int J Cancer 142:2163-2174
Soundararajan, Rama; Aparicio, Ana M; Logothetis, Christopher J et al. (2018) Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Front Oncol 8:69
Class, Caleb A; Ha, Min Jin; Baladandayuthapani, Veerabhadran et al. (2018) iDINGO-integrative differential network analysis in genomics with Shiny application. Bioinformatics 34:1243-1245
Lin, Song-Chang; Yu-Lee, Li-Yuan; Lin, Sue-Hwa (2018) Osteoblastic Factors in Prostate Cancer Bone Metastasis. Curr Osteoporos Rep 16:642-647
Wang, Hong; Yang, Xu; Liu, Anna et al. (2018) ?-Tocopherol inhibits the development of prostate adenocarcinoma in prostate specific Pten-/- mice. Carcinogenesis 39:158-169

Showing the most recent 10 out of 217 publications